Back to Search Start Over

Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies

Authors :
Peter Reiss
Margaret T May
Matthias Cavassini
Sophie Grabar
Christoph Wyen
Sophie Abgrall
Fabrice Bonnet
Julia del Amo
Amy C. Justice
Antonella d'Arminio Monforte
Ferdinand W. N. M. Wit
Katharina Grabmeier-Pfistershammer
Leah Shepherd
Ramón Teira
Juan Berenguer
M. John Gill
Adam Trickey
Jodie L. Guest
Janne Vehreschild
Dominique Costagliola
Jonathan A C Sterne
Gestionnaire, Hal Sorbonne Université
University of Bristol [Bristol]
University of Calgary
Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)
Groupe hospitalier Broca
University Hospital of Cologne [Cologne]
German Centre for Infection Research (DZIF)
University of Amsterdam [Amsterdam] (UvA)
Stichting HIV Monitoring [Amsterdam]
Universiteit van Amsterdam (UvA)
Amsterdam Institute for Global Health & Development [Amsterdam, The Netherlands]
VU University Medical Center [Amsterdam]
Bordeaux population health (BPH)
Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
CHU Bordeaux [Bordeaux]
Université de Lausanne = University of Lausanne (UNIL)
Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV)
Hôpital Antoine Béclère
Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)
Medizinische Universität Wien = Medical University of Vienna
Emory University School of Medicine
Emory University [Atlanta, GA]
University College of London [London] (UCL)
Università degli Studi di Milano = University of Milan (UNIMI)
Institute of Health Carlos III
Yale School of Medicine [New Haven, Connecticut] (YSM)
VA Connecticut Healthcare System
Department for International Development (Reino Unido)
NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos)
Medical Research Council (Reino Unido)
Unión Europea. Comisión Europea. 7 Programa Marco
Institut National de la Santé et de la Recherche Médicale (Francia)
Swiss National Science Foundation
Ministerio de Sanidad y Consumo (España)
Red de Investigación Cooperativa en Investigación en Sida (España)
National Institutes of Health (Estados Unidos)
Canadian Institutes of Health Research
Global Health
Infectious diseases
AII - Infectious diseases
APH - Aging & Later Life
Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université de Lausanne (UNIL)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
Università degli Studi di Milano [Milano] (UNIMI)
Yale University School of Medicine
United Kingdom Department for International Development
National Institute on Alcohol Abuse and Alcoholism (United States)
Medical Research Council (United Kingdom)
7º Programa Marco - Comisión Europea
Institut National de la Santé et de la Recherche Médicale
Red Española de Investigación en SIDA
National Institutes of Health (United States)
Source :
International Journal of Cancer, International Journal of Cancer, Wiley, 2020, 146 (11), pp.3134-3146. ⟨10.1002/ijc.32895⟩, Repisalud, Instituto de Salud Carlos III (ISCIII), International journal of cancer. Journal international du cancer, 146(11), 3134-3146. Wiley-Liss Inc., International journal of cancer, vol. 146, no. 11, pp. 3134-3146, Trickey, A, May, M T, Gill, M J, Grabar, S, Vehreschild, J-J, Wit, F W N M, Bonnet, F, Cavassini, M, Abgrall, S, Berenguer, J, Wyen, C, Reiss, P, Grabmeier-Pfisterhammer, K, Guest, J L, Shepherd, L, Teira, R, Monforte, A D A, Del Amo, J, Justice, A, Costagliola, D & Sterne, J A C 2020, ' Cause-specific mortality after diagnosis of cancer among HIV-positive patients : a collaborative analysis of cohort studies ', International Journal of Cancer, vol. 146, no. 11, pp. 3134-3146 . https://doi.org/10.1002/ijc.32895.
Publication Year :
2020

Abstract

People living with HIV (PLHIV) are more likely than the general population to develop AIDS‐defining malignancies (ADMs) and several non‐ADMs (NADMs). Information is lacking on survival outcomes and cause‐specific mortality after cancer diagnosis among PLHIV. We investigated causes of death within 5 years of cancer diagnosis in PLHIV enrolled in European and North American HIV cohorts starting antiretroviral therapy (ART) 1996–2015, aged ≥16 years, and subsequently diagnosed with cancer. Cancers were grouped: ADMs, viral NADMs and nonviral NADMs. We calculated cause‐specific mortality rates (MR) after diagnosis of specific cancers and compared 5‐year survival with the UK and France general populations. Among 83,856 PLHIV there were 4,436 cancer diagnoses. Of 603 deaths after ADM diagnosis, 292 (48%) were due to an ADM. There were 467/847 (55%) and 74/189 (39%) deaths that were due to an NADM after nonviral and viral NADM diagnoses, respectively. MR were higher for diagnoses between 1996 and 2005 versus 2006–2015: ADMs 102 (95% CI 92–113) per 1,000 years versus 88 (78–100), viral NADMs 134 (106–169) versus 111 (93–133) and nonviral NADMs 264 (232–300) versus 226 (206–248). Estimated 5‐year survival for PLHIV diagnosed with liver (29% [19–39%]), lung (18% [13–23%]) and cervical (75% [63–84%]) cancer was similar to general populations. Survival after Hodgkin's lymphoma diagnosis was lower in PLHIV (75% [67–81%]). Among ART‐treated PLHIV diagnosed with cancer, MR and causes of death varied by cancer type, with mortality highest for liver and lung cancers. Deaths within 5 years of NADM diagnoses were more likely to be from cancer than AIDS.<br />What's new? People with HIV live longer than they used to, thanks to advances in antiretroviral therapy. These improvements reduced the incidence of AIDS‐defining malignancies, such as Kaposi's sarcoma, but the increased life expectancy has led to more diagnoses of cancers not traditionally associated with HIV. Here, the authors studied cause‐specific mortality among people with HIV diagnosed with cancer. For those people, within 5 years after a cancer diagnosis, cause of death was more likely to be cancer than AIDS. Survival rates after diagnosis varied by cancer type, but were similar to rates among the general population.

Details

Language :
English
ISSN :
00207136 and 10970215
Database :
OpenAIRE
Journal :
International Journal of Cancer, International Journal of Cancer, Wiley, 2020, 146 (11), pp.3134-3146. ⟨10.1002/ijc.32895⟩, Repisalud, Instituto de Salud Carlos III (ISCIII), International journal of cancer. Journal international du cancer, 146(11), 3134-3146. Wiley-Liss Inc., International journal of cancer, vol. 146, no. 11, pp. 3134-3146, Trickey, A, May, M T, Gill, M J, Grabar, S, Vehreschild, J-J, Wit, F W N M, Bonnet, F, Cavassini, M, Abgrall, S, Berenguer, J, Wyen, C, Reiss, P, Grabmeier-Pfisterhammer, K, Guest, J L, Shepherd, L, Teira, R, Monforte, A D A, Del Amo, J, Justice, A, Costagliola, D & Sterne, J A C 2020, ' Cause-specific mortality after diagnosis of cancer among HIV-positive patients : a collaborative analysis of cohort studies ', International Journal of Cancer, vol. 146, no. 11, pp. 3134-3146 . https://doi.org/10.1002/ijc.32895.
Accession number :
edsair.doi.dedup.....feb2223dd5bd320379e1b0afd55215b3